NCT05849298 2026-04-13
PSMACare
Novartis
Phase 2 Active not recruiting
Clinical Trials
10 trialsNCT05114746 2026-04-01
Study of 177Lu-PSMA-617 In Metastatic Castrate-Resistant Prostate Cancer in Japan
Novartis
Phase 2 Active not recruiting
NCT04689828 2026-03-23
PSMAfore
Novartis
Phase 3 Active not recruiting
NCT04720157 2026-03-11
PSMAddition
Novartis
Phase 3 Active not recruiting
NCT06881823 2025-12-29
NeoPSMA
Novartis
Phase 1/2 Withdrawn
NCT05983198 2025-12-22
SatisfACtion
Novartis
Phase 1/2 Active not recruiting
NCT07052214 2025-09-10
BiPASS
Telix Pharmaceuticals (Innovations) Pty Limited
Phase 3 Recruiting
NCT04597411 2025-03-21
Study of 225Ac-PSMA-617 in Men With PSMA-positive Prostate Cancer
Endocyte
Phase 1 Recruiting
NCT05847348 2024-07-03
68Ga-PSMA-11 Efficacy in Detecting BCR Prostate Cancer in Chinese Patients
Telix Pharmaceuticals (Innovations) Pty Limited
Phase 3 Recruiting
NCT03822871 2024-03-21
A Trial of CTT1403 for Metastatic Castration Resistant Prostate Cancer
Cancer Targeted Technology
Phase 1 Completed